Clinical acceptance of a molecular imaging agent: a long march with [99mTc]TRODAT.
In the past 10 years, significant progress has been made in using a technetium-99m dopamine transporter imaging agent, [99mTc]TRODAT, for routine clinical studies. Developing a molecular imaging agent from bench to the bedside is more than a simple scientific venture. Currently, Taiwan is the only place where [99mTc]TRODAT is approved for routine clinical use in the diagnosis of Parkinson's disease. The trials and tribulations of developing [99mTc]TRODAT for routine clinical use in Taiwan provide an interesting case study in how to (critics may say, how not to) develop a molecular imaging agent.
Kung
Hank F
HF
Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA. kunghf@sunmac.spect.upenn.edu
Kung
Mei-Ping
MP
Wey
Shiaw-Pyng
SP
Lin
Kun-Ju
KJ
Yen
Tzu-Chen
TC
D001921:Brain / Q000000981:diagnostic imaging*; D006801:Humans; D015336:Molecular Probe Techniques / Q000639:trends*; D015609:Organotechnetium Compounds; D010300:Parkinson Disease / Q000000981:diagnostic imaging*; D010818:Practice Patterns, Physicians' / Q000639:trends*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013624:Taiwan; D014326:Tropanes
D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D014326:Tropanes; C104196:technetium Tc 99m TRODAT-1